english.prescrire.org > Spotlight > 100 most recent > Prescrire's ratings: new drugs and indications, at a glance


Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Prescrire's ratings: new drugs and indications, at a glance

 ABOUT PRESCRIRE  Each month, Prescrire's editors review new drugs and new indications, to assess whether or not they represent a therapeutic advance for patients. Our unique ratings system sums up this detailed, evidence-based opinion at a glance.

Reviews are produced according to a rigorous, evidence-based procedure by members of Prescrire's Editorial Staff, all specially trained healthcare professionals who sign an annual declaration of absence of conflicts of interest.

Here is a guide to what these ratings mean. This guide is also printed in the "New Products" section of each issue of Prescrire International.

Our judgement is based on the therapeutic advance of the new product. It considers not only the inherent value of each product in terms of its harm-benefit balance, but also its advantages and disadvantages relative to existing products available in France. Note that the relative value of new products can vary from one country to another.

Prescrire's ratings


©Prescrire 1 March 2017

For more information:

How we work
(November 2016)

Meet Gaspard
(November 2016)

See also:

ISDB Declaration
on therapeutic advance
in the use of medicines
(November 2001)
Pdf, free

The Prescrire
Awards for 2016
(February 2017)